EE672 Cost-Effectiveness Analysis of Pembrolizumab for the Adjuvant Treatment of Patients With Renal Cell Carcinoma Who Have Undergone Nephrectomy in Greece
Dec 1, 2023, 00:00 AM
10.1016/j.jval.2023.09.937
https://www.valueinhealthjournal.com/article/S1098-3015(23)04067-6/fulltext
Section Title :
Section Order :
10433
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)04067-6&doi=10.1016/j.jval.2023.09.937